These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28318723)

  • 1. Pan-European survey of the topical ocular use of cyclosporine A.
    Labbé A; Baudouin C; Ismail D; Amrane M; Garrigue JS; Leonardi A; Figueiredo FC; Van Setten G; Labetoulle M
    J Fr Ophtalmol; 2017 Mar; 40(3):187-195. PubMed ID: 28318723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cyclosporine eye drops: A 4-year retrospective study (2009-2013)].
    Kauss Hornecker M; Charles Weber S; Brandely Piat ML; Darrodes M; Jomaa K; Chast F
    J Fr Ophtalmol; 2015 Oct; 38(8):700-8. PubMed ID: 26371985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Topical cyclosporine in ophthalmology: Pharmacology and clinical indications].
    Levy O; Labbé A; Borderie V; Laroche L; Bouheraoua N
    J Fr Ophtalmol; 2016 Mar; 39(3):292-307. PubMed ID: 26997607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Topical cyclosporine A and risk of ocular surface neoplasia].
    Rouimi F; Bouillot A; Baudouin C; Labbé A
    J Fr Ophtalmol; 2018 Feb; 41(2):122-128. PubMed ID: 29402465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical ophthalmic cyclosporine: pharmacology and clinical uses.
    Donnenfeld E; Pflugfelder SC
    Surv Ophthalmol; 2009; 54(3):321-38. PubMed ID: 19422961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis.
    Pucci N; Caputo R; Mori F; De Libero C; Di Grande L; Massai C; Bernardini R; Novembre E
    Int J Immunopathol Pharmacol; 2010; 23(3):865-71. PubMed ID: 20943058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. The European Pharmacovigilance Research Group.
    Belton KJ
    Eur J Clin Pharmacol; 1997; 52(6):423-7. PubMed ID: 9342576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts.
    Lallemand F; Schmitt M; Bourges JL; Gurny R; Benita S; Garrigue JS
    Eur J Pharm Biopharm; 2017 Aug; 117():14-28. PubMed ID: 28315447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opinions on risk factors and management of corneal graft rejection in the United kingdom.
    Koay PY; Lee WH; Figueiredo FC
    Cornea; 2005 Apr; 24(3):292-6. PubMed ID: 15778601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence.
    Zimmerman TJ; Hahn SR; Gelb L; Tan H; Kim EE
    J Ocul Pharmacol Ther; 2009 Apr; 25(2):145-52. PubMed ID: 19284321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A prospective, observational, all-prescribed-patients study of cyclosporine 0.1% ophthalmic solution in the treatment of vernal keratoconjunctivitis].
    Takamura E; Uchio E; Ebihara N; Okamoto S; Kumagai N; Shoji J; Nakagawa Y; Namba K; Fukushima A; Fujishima H; Miyazaki D; Ohashi Y
    Nippon Ganka Gakkai Zasshi; 2011 Jun; 115(6):508-15. PubMed ID: 21735754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus vs. cyclosporine eyedrops in severe cyclosporine-resistant vernal keratoconjunctivitis: A randomized, comparative, double-blind, crossover study.
    Pucci N; Caputo R; di Grande L; de Libero C; Mori F; Barni S; di Simone L; Calvani A; Rusconi F; Novembre E
    Pediatr Allergy Immunol; 2015 May; 26(3):256-261. PubMed ID: 25712437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.
    Di Tommaso C; Bourges JL; Valamanesh F; Trubitsyn G; Torriglia A; Jeanny JC; Behar-Cohen F; Gurny R; Möller M
    Eur J Pharm Biopharm; 2012 Jun; 81(2):257-64. PubMed ID: 22445900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical cyclosporine A in severe steroid-dependent childhood phlyctenular keratoconjunctivitis.
    Doan S; Gabison E; Gatinel D; Duong MH; Abitbol O; Hoang-Xuan T
    Am J Ophthalmol; 2006 Jan; 141(1):62-66. PubMed ID: 16386977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative approach to topical cyclosporine therapy.
    Williams DL
    Eye (Lond); 1997; 11 ( Pt 4)():453-64. PubMed ID: 9425407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD; Pflugfelder SC; Tauber J; Foulks GN
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes.
    Price MO; Price FW
    Ophthalmology; 2006 Oct; 113(10):1785-90. PubMed ID: 16884779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis.
    Ebihara N; Ohashi Y; Uchio E; Okamoto S; Kumagai N; Shoji J; Takamura E; Nakagawa Y; Nanba K; Fukushima A; Fujishima H
    J Ocul Pharmacol Ther; 2009 Aug; 25(4):365-72. PubMed ID: 19441889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of a risk-minimization activity involving physician education on metabolic monitoring of patients receiving quetiapine: results from two postauthorization safety studies.
    Brody RS; Liss CL; Wray H; Iovin R; Michaylira C; Muthutantri A; Damstetter P; Datto C; Jefferies L
    Int Clin Psychopharmacol; 2016 Jan; 31(1):34-41. PubMed ID: 26451964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.